comparemela.com

Latest Breaking News On - Ziftomenib - Page 1 : comparemela.com

FDA Grants Breakthrough Therapy Designation to Ziftomenib in NPM1-Mutant AML

The FDA has granted breakthrough therapy designation to ziftomenib for the treatment of NPM1-mutant acute myeloid leukemia.

Troy wilsonKura oncologyNpm1 mutant acute myeloid leukemia

Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML

An acceptable safety profile and early evidence of clinical activity was observed with ziftomenib plus standard regimens in select patients with AML.

Samer zeidanDivision of hematologic malignanciesHematologic malignanciesHematology early therapeutics researchYale cancer centerPhase 1 2 komet 007 trialAcute myeloid leukemiaNpm1 mutant and kmt2a rearrangedNpm1 mutant and kmt2a rearranged amlCytarabine and daunorubicin 7 3

Kura Gains 17% Over Positive Preliminary Clinical Data From Phase 1 Trial Of Ziftomenib

Stock of Kura Oncology, Inc. (KURA) gained 15 percent on Tuesday morning after the company announced positive preliminary clinical data from phase 1 trial Of Ziftomenib.

United kingdomEngland prudential regulation authorityGeneral motors coNew york stock exchangeDrug administrationYork stock exchangeNeptune resourcesHoldings plcGeneral motorsNew york stockPrudential regulation authorityUra oncologyReliminary clinical data

Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed or Refractory NPM1-Mutated AML

Expert Amir Fathi, MD, reviews recent clinical data with ziftomenib in patients with relapsed/refractory acute myeloid leukemia.

Amir fathiResistance profileMenin inhibitor ziftomenibAdults withAcute myeloid leukemiaNpm1 mutationsRelapsed refractory amlNovel therapyClinical trialSafety profileAdverse eventsDrug adverse eventMrd testingMinimal residual diseaseMenin inhibitorsMenin inhibition

Dr Fathi on Ziftomenib in R/R NPM1-Mutant AML

Amir Fathi, MD, discusses findings from the phase 1b expansion portion of the phase 1/2 KOMET-001 trial in patients with relapsed/refractory acute myeloid leukemia harboring NPM1 mutations.

United statesAmir fathiHarvard medical schoolMassachusetts general hospitalKomet 001 trialPatients with relapsed refractory acute myeloid leukemia harboring npm1 mutations

vimarsana © 2020. All Rights Reserved.